Vera Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United St...
Latest News
4 days ago · 247wallst.com
He Takes a New Job at 64 With a $100,000 Stock Grant. When the Shares Vest, Social Security Could Withhold His Retirement Checks Even Though He Hasn’t Sold a Single ShareA 64-year-old collecting Social Security takes a job with a juicy stock grant and assumes unsold shares can't touch his checks. The day those shares vest, a rule most workers never hear about may prove him wrong.
10 days ago · marketbeat.com
Vera Therapeutics Q3 Earnings Call HighlightsVera Therapeutics NASDAQ: VERA reported $10.3 million in third-quarter TRUTAKNA sales, its first partial quarter of commercial revenue, as the company pursues full U.S. approval for the kidney disease treatment.
11 days ago · seekingalpha.com
Vera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call TranscriptVera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
11 days ago · zacks.com
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue EstimatesVera Therapeutics, Inc. (VERA) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to a loss of $1.26 per share a year ago.
15 days ago · globenewswire.com
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceBRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, which is taking place in Boston, MA from November 9-11, 2026.
25 days ago · marketbeat.com
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy ResultsVera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology's Kidney Week meeting in Denver, alongside publication in The New England Journal of Medicine.
25 days ago · seekingalpha.com
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy TranscriptVera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
26 days ago · globenewswire.com
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineTRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events. Favorable safety profile, and generally comparable to placebo.
28 days ago · globenewswire.com
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastInvestor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026 Q3 2026 financial results investor webcast scheduled at 4:30 p.m.
2 months ago · globenewswire.com
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VERA